PMID- 35698267
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220907
IS  - 1386-6346 (Print)
IS  - 1386-6346 (Linking)
VI  - 52
IP  - 9
DP  - 2022 Sep
TI  - Transarterial chemoembolization combined with lenvatinib versus transarterial 
      chemoembolization combined with sorafenib for unresectable hepatocellular 
      carcinoma: A comparative retrospective study.
PG  - 794-803
LID - 10.1111/hepr.13801 [doi]
AB  - AIM: Tyrosine kinase inhibitors target transarterial chemoembolization 
      (TACE)-mediated vascular endothelial growth factor to inhibit tumor 
      revascularization and to slow tumor progression. The present study aimed to 
      compare the clinical outcomes of TACE combined with lenvatinib (TACE-lenvatinib) 
      and TACE combined with sorafenib (TACE-sorafenib) in patients with unresectable 
      hepatocellular carcinoma (HCC). METHODS: The clinical data of patients diagnosed 
      with unresectable HCC who received TACE-lenvatinib or TACE-sorafenib between 
      January 2018 and April 2021 were retrospectively reviewed. The tumor response, 
      progression-free survival (PFS), overall survival (OS), and adverse events (AEs) 
      were evaluated and compared between the two groups. RESULTS: A total of 112 
      patients were enrolled and classified into the TACE-lenvatinib group (n = 53) and 
      the TACE-sorafenib group (n = 59). The objective response rates of patients in 
      the TACE-lenvatinib and TACE-sorafenib groups were 54.7% and 44.1%, respectively 
      (p = 0.260), and the disease control rates (DCRs) were 81.1% and 61.0% 
      (p = 0.020). The median PFS time was significantly longer in the TACE-lenvatinib 
      group than in the TACE-sorafenib group (10.7 vs. 6.0 months; p = 0.002). The 
      median OS time between the TACE-lenvatinib and TACE-sorafenib groups also showed 
      a significant difference (30.5 vs. 20.5 months, p = 0.018). All treatment-related 
      AEs and grade 3/4 AEs were comparable between the two groups (p > 0.05). 
      CONCLUSION: Compared to TACE-sorafenib, TACE-lenvatinib was associated with 
      better DCR, PFS and OS outcomes in patients with unresectable HCC. In subgroups 
      of Barcelona Clinic Liver Cancer B stage or TACE-refractory patients, 
      TACE-lenvatinib also showed a trend of superiority.
CI  - (c) 2022 Japan Society of Hepatology.
FAU - Zhang, Jin-Xing
AU  - Zhang JX
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing, China.
FAU - Chen, Yu-Xing
AU  - Chen YX
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing, China.
FAU - Zhou, Chun-Gao
AU  - Zhou CG
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing, China.
FAU - Liu, Jin
AU  - Liu J
AD  - Department of Clinical Medicine Research Institution, The First Affiliated 
      Hospital with Nanjing Medical University, Nanjing, China.
FAU - Liu, Sheng
AU  - Liu S
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing, China.
FAU - Shi, Hai-Bin
AU  - Shi HB
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing, China.
FAU - Zu, Qing-Quan
AU  - Zu QQ
AUID- ORCID: 0000-0001-7359-0791
AD  - Department of Interventional Radiology, The First Affiliated Hospital with 
      Nanjing Medical University, Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20220630
PL  - Netherlands
TA  - Hepatol Res
JT  - Hepatology research : the official journal of the Japan Society of Hepatology
JID - 9711801
OTO - NOTNLM
OT  - carcinoma
OT  - chemoembolization
OT  - hepatocellular
OT  - lenvatinib
OT  - sorafenib
OT  - therapeutic
EDAT- 2022/06/15 06:00
MHDA- 2022/06/15 06:01
CRDT- 2022/06/14 00:03
PHST- 2022/05/31 00:00 [revised]
PHST- 2021/12/19 00:00 [received]
PHST- 2022/06/03 00:00 [accepted]
PHST- 2022/06/15 06:00 [pubmed]
PHST- 2022/06/15 06:01 [medline]
PHST- 2022/06/14 00:03 [entrez]
AID - 10.1111/hepr.13801 [doi]
PST - ppublish
SO  - Hepatol Res. 2022 Sep;52(9):794-803. doi: 10.1111/hepr.13801. Epub 2022 Jun 30.